Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

toripalimab 2Injections 2ulixertinib 1tislelizumab 1spartalizumab 1lenvatinib 1famitinib 1erdafitinib 1camrelizumab 1Oxaliplatin 1Leucovorin 1Irinotecan 1Gemcitabine 1Docetaxel 1Cisplatin 1Capecitabine 15-fluorouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumor × lenvatinib × Clear all
NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
58 enrolled 16 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡